Black Diamond Therapeutics, Inc. (BDTX) has a consensus analyst rating of Buy, based on 10 analysts covering the stock. Of those, 9 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for BDTX is $8.00, representing a +200.8% upside from the current price of $2.66. Price targets range from a low of $8.00 to a high of $8.00.
